68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
Recruiting · NCT06559371 · Observational (researchers observe without assigning treatment) · Lead sponsor: Kunwei Shen
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this observational study is to learn whether 68Ga-FAPI PET/CT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer. The main question it aims to answer is: Could 68Ga-FAPI PET/CT effectively evaluate axillary lymph node after neoadjuvant treatment for breast cancer? Participants will have a 68Ga-FAPI PET/CT test between last neoadjuvant therapy and surgery.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Female patients aged 18 and above
- ECOG score 0-2 points
- Pathological confirmation of malignant breast tumor
- Clinical axillary lymph node positivity (cN+)
- Completed at least 3 courses of neoadjuvant therapy and subjected to undergo surgical treatment
- Informed consent form signed
Exclusion criteria
- Distant metastasis
- Unable to complete the proposed neoadjuvant therapy plan
- Pregnancy
Where it is running
1 location listed.
- Shanghai Jiao Tong University School of Medicine, Ruijin Hospital - Shanghai, Shanghai Municipality, China